Literature DB >> 19207710

The use of symptoms to predict colorectal cancer site. Can we reduce the pressure on our endoscopy services?

A J Kent1, D Woolf, J McCue, S M Greenfield.   

Abstract

OBJECTIVE: Our objective was to determine the value of gastrointestinal symptoms and signs in predicting the site of colorectal cancer (CRC). These symptoms can subsequently be used in determining first-line investigation with either sigmoidoscopy or colonoscopy.
METHOD: We interrogated the endoscopic and CRC databases ('Infoflex'), for patients diagnosed with CRC between April 2005 and March 2006 inclusive. These patients were cross-referenced with the pathology database and patient records. Information gathered from these databases include: age, gender, symptoms, site of cancer, histology, Duke's grading, blood parameters, diagnostic tool and treatment.
RESULTS: One hundred fifty-three patients were diagnosed with CRC between April 2005 and March 2006. One hundred twenty-six were initially seen in the out-patient department, of whom 38 (29%) were right-sided (proximal to the splenic flexure), and 88 (70%) were left-sided (splenic flexure and beyond). Change in bowel habit (diarrhoea and constipation) and rectal bleeding were significantly associated with left-sided cancers (P < 0.0024 and P < 0.0001, respectively). Haemoglobin (P < 0.0001) and mean corpuscular volume (P < 0.0001) were significantly lower in right-sided cancers. Weight loss, pain and obstruction were not associated with cancer site. C-reactive protein, albumin and carcinoembryonic antigen are not predictive of cancer site, Duke's stage or influenced by patient age or gender. DISCUSSION: Symptoms can accurately predict site of cancer, allowing investigations to be tailored accordingly. We would recommend that patients with altered bowel habit and/or rectal bleeding, and no other symptoms, risk factors or anaemia, can be investigated with a flexible sigmoidoscopy to confirm or refute a diagnosis of colorectal cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19207710     DOI: 10.1111/j.1463-1318.2009.01770.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  6 in total

1.  Can the colour of per-rectal bleeding estimate the risk of lower gastrointestinal bleeding caused by malignant lesion?

Authors:  Pui-Yan Lai; Kin-Wai Chan; Carlos King-Ho Wong; William Meng; Wan Luk
Journal:  Int J Colorectal Dis       Date:  2015-10-31       Impact factor: 2.571

2.  Does body mass index impact the number of LNs harvested and influence long-term survival rate in patients with stage III colon cancer?

Authors:  Yi-Hung Kuo; Kam-Fai Lee; Chih-Chien Chin; Wen-Shih Huang; Chung-Hung Yeh; Jeng-Yi Wang
Journal:  Int J Colorectal Dis       Date:  2012-05-25       Impact factor: 2.571

3.  Safe investigation of isolated change in bowel habit with a flexible sigmoidoscopy? A systematic review and meta-analysis.

Authors:  Pjj Herrod; H Boyd-Carson; B Doleman; Jem Blackwell; Ejo Hardy; F Harper; J N Lund
Journal:  Ann R Coll Surg Engl       Date:  2019-03-11       Impact factor: 1.891

4.  Clinical and endoscopic-pathological characteristics of colorectal polyps: an analysis of 1,234 cases.

Authors:  Xiaohua Long; Xiaofeng Li; Lin Ma; Jing Lu; Suhuan Liao; Ruohu Gui
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Preoperative constipation is associated with poor prognosis of rectal cancer: a prospective cohort study.

Authors:  Gil-Yong Lee; Sung-Min Lee; Je-Ho Jang; Heung-Kwon Oh; Duck-Woo Kim; Soyeon Ahn; Sung-Bum Kang
Journal:  J Korean Surg Soc       Date:  2013-06-26

6.  Whole-colon investigation vs. flexible sigmoidoscopy for suspected colorectal cancer based on presenting symptoms and signs: a multicentre cohort study.

Authors:  Amanda J Cross; Kate Wooldrage; Emma C Robbins; Kevin Pack; Jeremy P Brown; William Hamilton; Michael R Thompson; Karen G Flashman; Steve Halligan; Siwan Thomas-Gibson; Margaret Vance; Brian P Saunders; Wendy Atkin
Journal:  Br J Cancer       Date:  2018-12-19       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.